Cargando…

Targeting metabolic reprogramming in chronic lymphocytic leukemia

Metabolic reprogramming, fundamentally pivotal in carcinogenesis and progression of cancer, is considered as a promising therapeutic target against tumors. In chronic lymphocytic leukemia (CLL) cells, metabolic abnormalities mediate alternations in proliferation and survival compared with normal B c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nie, Yu, Yun, Xiaoya, Zhang, Ya, Wang, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235173/ https://www.ncbi.nlm.nih.gov/pubmed/35761419 http://dx.doi.org/10.1186/s40164-022-00292-z

Ejemplares similares

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia
por: Yun, Xiaoya, et al.
Publicado: (2020)

Targeting Metabolic Reprogramming in Acute Myeloid Leukemia
por: Castro, Isabel, et al.
Publicado: (2019)

Platelet-derived microparticles provoke chronic lymphocytic leukemia malignancy through metabolic reprogramming
por: Gharib, Ehsan, et al.
Publicado: (2023)

Targeted treatment for chronic lymphocytic leukemia
por: Masood, Aisha, et al.
Publicado: (2011)

Therapeutic advancement of chronic lymphocytic leukemia
por: Lu, Kang, et al.
Publicado: (2012)

Phenotypic alteration of CD8(+) T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming
por: Wu, Jiazhu, et al.
Publicado: (2016)

Targeting the tumor microenvironment in chronic lymphocytic leukemia
por: Svanberg, Rebecka, et al.
Publicado: (2021)

Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia
por: Yun, Xiaoya, et al.
Publicado: (2021)

Nucleolar and spindle associated protein 1 enhances chemoresistance through DNA damage repair pathway in chronic lymphocytic leukemia by binding with RAD51
por: Han, Yang, et al.
Publicado: (2021)

Promises and pitfalls of targeted agents in chronic lymphocytic leukemia
por: Lew, Thomas E., et al.
Publicado: (2020)

Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia
por: Feng, Lili, et al.
Publicado: (2023)

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
por: Smolej, Lukáš
Publicado: (2014)

Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs
por: Vitale, Candida, et al.
Publicado: (2020)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

Therapeutic Targets in Chronic Lymphocytic Leukemia
por: Laurenti, Luca, et al.
Publicado: (2020)

Insights on Metabolic Reprogramming and Its Therapeutic Potential in Acute Leukemia
por: Di Martino, Ludovica, et al.
Publicado: (2021)

Lenalidomide and Chronic Lymphocytic Leukemia
por: González-Rodríguez, Ana Pilar, et al.
Publicado: (2013)

Update in the management of chronic lymphocytic leukemia
por: Maddocks, Kami J, et al.
Publicado: (2009)

Apoptosis inducers in chronic lymphocytic leukemia
por: Billard, Christian
Publicado: (2013)

Novel agents for chronic lymphocytic leukemia
por: Wu, Mei, et al.
Publicado: (2013)

Cardiac Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
por: Robak, Tadeusz, et al.
Publicado: (2022)

Metabolic reprogramming heterogeneity in chronic kidney disease
por: Miguel, Verónica, et al.
Publicado: (2023)

PB1951: PROGNOSTIC SIGNIFICANCE OF CLINICAL INDICATORS RELATED TO AMINO ACID METABOLISM IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Liu, Ming, et al.
Publicado: (2023)

Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia
por: Roy Chowdhury, Subir, et al.
Publicado: (2018)

Decreased deformability of lymphocytes in chronic lymphocytic leukemia
por: Zheng, Yi, et al.
Publicado: (2015)

Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets
por: Andreani, Giacomo, et al.
Publicado: (2020)

Targeting Lipid Metabolic Reprogramming as Anticancer Therapeutics
por: Cha, Ji-Young, et al.
Publicado: (2016)

Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma
por: Pang, Yuyang, et al.
Publicado: (2023)

Oncogene-Induced Reprogramming in Acute Lymphoblastic Leukemia: Towards Targeted Therapy of Leukemia-Initiating Cells
por: Fregona, Vincent, et al.
Publicado: (2021)

Allogeneic Transplantation for Chronic Lymphocytic Leukemia
por: Laurenti, Luca, et al.
Publicado: (2010)

Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia
por: Cortelezzi, Agostino, et al.
Publicado: (2012)

Infectious Complications in Chronic Lymphocytic Leukemia
por: Nosari, Annamaria
Publicado: (2012)

Advances in treating chronic lymphocytic leukemia
por: Tausch, Eugen, et al.
Publicado: (2014)

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
por: D'Arena, Giovanni, et al.
Publicado: (2013)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

Chronic lymphocytic leukemia at ASH 2017
por: Wanner, David, et al.
Publicado: (2018)

Infections in patients with chronic lymphocytic leukemia
por: Guarana, Mariana, et al.
Publicado: (2023)

Metabolic Reprogramming During Multidrug Resistance in Leukemias
por: Vidal, Raphael Silveira, et al.
Publicado: (2018)

New emerging therapies in the management of chronic lymphocytic leukemia
por: Li, Xiao-Lin, et al.
Publicado: (2016)

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
por: Schieber, Michael, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ogik46o5o0sce5ls9hugmm8p1q